Pfizer, Astellas win FDA priority review for Padcev in bladder cancer with Merck’s Keytruda

Pfizer (PFE) and Astellas (ALPMF) (ALPMY) announced Monday that the FDA has granted priority review for their marketing application, which seeks U.S. approval for their antibody drug conjugate, Padcev ...
The Bakersfield Californian

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

Pfizer Inc. (NYSE: PFE) will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 – June 2, ...

Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy

Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their ...

Scientists are working on a vaccine for cancer. Here’s how it would work

Scientists could soon develop personalized cancer vaccines.

BCAN Names Ferring Pharmaceuticals and the Astellas/Pfizer Alliance as National Presenting Sponsors of the 2026 Walks to End Bladder Cancer

The Bladder Cancer Advocacy Network (BCAN) today announced that Ferring Pharmaceuticals and the Astellas/Pfizer Alliance will serve as National Presenting Sponsors of the 2026 Walks to End Bladder ...

Merck, Pfizer, Astellas Drug Combo Gets Speedy FDA Review in Bladder Cancer

Merck in 2019 signed a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Padcev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late ...